pharmaphorum

JANUARY 29, 2021

Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. The genomic medicine journey. Zinc fingers.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Pharma Marketing Network

DECEMBER 21, 2020

Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

The Pharma Data

MARCH 7, 2022

Researchers from the University of Washington School of Medicine in Seattle describe this finding in the journal Cell Reports. “The beauty of this approach is we can safely upregulate specific genes to affect cell activity without permanently changing the genome and cause unintended mistakes,” Levy said. .

Protein 52

Protein Gene Genome Genomics 52

XTalks

DECEMBER 24, 2020

From rare disease drug approvals to treatments involving immunotherapies and gene therapies and awarding of a Nobel Prize to the inventors of the gene-editing tool CRISPR, 2020 was a year of great activity and productivity despite the backdrop of the pandemic. CRISPR Gene Editing Inventors Win Nobel Prize.

Life Science 111

Life Science Vaccination Vaccine Gene 111

XTalks

FEBRUARY 11, 2021

Geneticist Martha Chase was a key partner of the foundational Hershey-Chase experiment that helped confirm DNA to be the carrier of genetic information; however, it was only Hershey of the pair that went on to win the Nobel Prize in Physiology or Medicine in 1969 for the discovery. Chase’s exclusion from the prize remains a mystery.

Genetics 119

Genetics DNA Genome Genomics 119

XTalks

SEPTEMBER 21, 2020

The study was published in the journal Science Translational Medicine. The gene, called KDM6A , is a histone demethylase that is believed to function as a tumor suppressor. Increasing KDM6A expression in male mice led them to be more resilient to the effects of amyloid beta plaques. KDM6A Variant.

Gene 89

Gene Protein Gene Expression Scientist 89